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(57) ABSTRACT 
Apparatus and methods are directed to a perfusion culture 
system in which a rotating bioreactor is used to grow cells 
in a liquid culture medium, while these cells are attached to 
an adhesive-treated porous surface. As a result of this 
arrangement and its rotation, the attached cells divide, with 
one cell remaining attached to the substrate, while the other 
cell, a newborn cell is released. These newborn cells are of 
approximately the same age, that are collected upon leaving 
the bioreactor. The populations of newborn cells collected 
are of synchronous and are minimally, if at all, disturbed 
metabolically. 
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erated cells, they did not generate newborn cells and could 
not continuously generate cells. 
SUMMARY 
5 The present invention is directed to systems, apparatus 
and methods for producing newborn cells from a culture in 
continuous steady-state growth. Additionally, these newborn 
cells are produced continuously, automatically and under 
simulated microgravity conditions. The apparatus is directed 
10 to a perfusion culture system in which a rotating bioreactor 
is used to grow cells in a liquid culture medium. Within this 
bioreactor, these cells are attached to an adhesive-treated 
porous surface, that is continuously perfused with culture 
medium. This attachment allows cells to divide, with one of 
15 the cells remaining bound to the porous surface while the 
other newborn cell moves toward a collection device. The 
cell that remains has not been changed metabolically, and 
can continue to divide and produce newborn cells. This 
results in cell populations of the same age being collected 
20 and the populations of these newborn cells collected are of 
synchronous and not disturbed metabolically. 
Additionally, the rotation is typically performed at speeds 
that subject the cells to averaging of the gravity vector (or 
simulated microgravity conditions). This rotation, coupled 
2s with the continuous perfusion of culture medium on the 
porous surface, allows the attached cells to divide, releasing 
newborn cells, that are collected upon leaving the bioreactor. 
The cells produced in accordance with the invention can be 
analyzed to determine gravitational impacts on cell growth, 
30 the cell cycle, cell differentiation and cell aging. Also, the 
cells produced could be particularly useful in cancer or 
aging research, as well as studies of the effects of gravity on 
cells. 
There is disclosed apparatus for producing synchronous 
3s cells having a vessel configured for being rotated and a 
substrate configured for rotating with the vessel, the sub- 
strate configured for holding cells while rotating with the 
vessel. There is also a system for perfusing the substrate with 
at least one culture medium. This perfusion is typically 
There is disclosed an embodiment of a method (process) 
for producing synchronous cells. This method includes 
providing a bioreactor having a substrate configured for 
holding cells and rotating in the bioreactor, holding the cells 
at least proximate to said substrate, rotating the substrate, 
and perfusing the substrate with at least one culture medium. 
There is disclosed another embodiment of a method 
(process) for producing synchronous cells. This method 
so includes providing a bioreactor having a vessel configured 
for being rotated; and a substrate for holding cells. The 
substrate is configured for rotating with the vessel. Cells are 
then attached to the substrate; and the vessel is rotated to 
rotate the substrate. 
40 continuous while the substrate is rotating. 
4s 
BRIEF DESCRIPTION OF THE DRAWINGS 5s 
Attention is now directed to the drawings, where like 
numerals and characters indicate like or corresponding com- 
ponents. In the drawings: 
FIG. 1 is a perspective view of an embodiment of the 
invention; and 
FIG. 2 is a schematic diagram of the embodiment of FIG. 
1. 
60 
6s DETAILED DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows an embodiment of the system 20. The 
system 20, includes an apparatus 20a, that includes a frame 
1 
BIOREACTOR AND METHODS FOR 
PRODUCING SYNCHRONOUS CELLS 
CROSS-REFERENCES TO RELATED 
APPLICATIONS 
This application is a continuation in part application of 
U.S. patent application Ser. No. 101080,333, entitled: 
METHOD FOR PRODUCING SYNCHRONOUS CELLS 
AND THE RESULTANT CELLS, filed on Feb. 21, 2002, 
which is based on U.S. Provisional Patent Application Ser. 
No. 601273,775, entitled: METHOD FOR PRODUCING 
SYNCHRONOUS CELLS AND THE RESULTANT 
CELLS, filed on Mar. 2, 2001, both of these applications 
incorporated by reference herein. 
GOVERNMENT SUPPORT 
Support for the invention disclosed herein is from the 
National Aeronautics and Space Administration (NASA) 
NAG8-1582 “New Cell Culture Technology” and NASA 
NAG2-1508 “Gravitational Impacts On The Cell Cycle”. 
TECHNICAL FIELD 
The present invention relates to apparatus and methods 
for producing synchronous cells and in particular newborn 
cells of a uniform culture, and in particular, a rotating 
bioreactor apparatus that grows cells in liquid culture media. 
BACKGROUND 
Thousands of biological research and development facili- 
ties worldwide deal with some aspect of the growth and 
division of cells. Suspensions of minimally disturbed new- 
born cells are valuable for analysis of the cell cycle, includ- 
ing analysis of all mammalian cell types. The newborn cell 
suspensions can be used to analyze cell cycle gene expres- 
sion in mammalian cells, such as hematopoietic cells. Grow- 
ing and dividing cells are used in basic research, drug 
development and testing, and bio-product manufacturing, 
for example. 
Furthermore, during the past few years there has been a 
significant expansion in research in the related areas of cell 
cycle regulation, cell senescence, apoptosis, and cellular 
differentiation. Studies related to these specific areas require 
access to, and reliable production of, large quantities of cells 
that are at a specific, known phase of growth and division, 
such as a particular stage in the cell cycle, and state of 
senescence. 
Obtaining adequate quantities of synchronous cells whose 
physiology is minimally disturbed, is not an easy task. This 
is because contemporary production methods expose cells to 
metabolic disturbances, such as with the addition of drugs or 
deprivation of nutrients, in order to obtain an exponentially 
growing culture of cells, where the population is distributed 
throughout all phases of the cell cycle, to become growth 
inhibited at a particular stage in the cell cycle. Even if these 
methods are successful, it is unclear if these cellular events 
represent the true “steady state” of the cells, where all 
biochemical and metabolic processes are in balance or an 
artifact created by the disturbance. 
Attempts have been made to produce devices and meth- 
ods for manufacturing large quantities of cells that are at 
specific stages in cell cycles and senescence. For example, 
U.S. Pat. No. 6,001,642 (Tsao) and U.S. Pat. No. 5,153,131 
(Wolf) are directed to bioreactors that grow cells in suspen- 
sion or are attached to a substrate for three-dimensional 
tissue or organ growth. However, while these devices gen- 
US 6,867,040 B2 
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21 that supports a bioreactor 22, rotated by a drive system, divide without damaging them. The adhesives can include 
typically formed of a belt drive 23 and pulleys 24h, 24m, any composition that binds to a cell surface and can be 
coupled with a motor 25 and regulator (not shown). Also anchored or attached to the substrate 46. Exemplary adhe- 
included is a fluid coupler 26, coupled to a rotatable neck 27 sives include proteins, which bind to the specific cell surface 
and reservoir 28 or fluid source, respectively. The fluid s receptors, such as lectins (or lectin based compositions) that 
coupler 26 has an exit port 30, that typically empties into a bind cell surface components, such as Concanavalin A, 
collection flask 32. charged molecules  (or charged molecule based 
An axle 40, having ends 41a, 41b, rotated by the motor comPositions), that bind to cell surfaces, such as Poly-D- 
25, provides rotation to the bioreactor 22. A first end 41a of lysine, antibodies (Or antibody based comPositions) (W.2 
the axle 40 connects to the housing pulley 24h, while the 10 antibodies to cell surface components), other adhesives, 
second end 41b connects to the bioreactor 22, typically at the such as fibronectin (fibronectin based comPositions), as well 
vessel 42. The axle 40 and rotatable neck 27 are typically as other substances and comPositions that when Placed onto 
coaxial, along a horizontal axis H. the substrate 46 will bind and/or provide binding sites for the 
The bioreactor 22 is formed from the vessel 42, including 
an outer shell 44 and a culture chamber 45, a porous The spacer 50 is typically a thin member Placed into 
substrate 46, for example, a membrane, a spacer 50, and a contact with the Plate 52. This spacer 50 creates a uniform 
plate 52, typically with a flat surface 53. These elements are space between the cells 66 attached to the substrate 46 and 
typically in a concentric alignment, and are typically sub- the Plate 5% SO that newborn cells can move out of the Port 
stantially perpendicular to the axle 40 and the neck 27 and 70 in the Plate 52 rapidly, without getting caught in crevices 
substantially parallel to each other. The vessel 42 typically 2o and the like. The spacer 50 is for example, a DACRON@ 
clamps to the plate 52 by bolts 54 (of stainless steel or the mesh, approximately 0.2 mm thick and having openings of 
like) holding the substrate and spacer 50 in place, The vessel about 1 square millimeter each. This results in the volume of 
42, closed by the plate 52, defines an effluent chamber 56 in medium between the attached cells 66 and the flat Plate 52 
its interior, ne rotation of the axle 40 and neck 27 (as being typically not more than approximately 2.0 milliliters 
rotated by the drive system), typically rotates the bioreactor 25 (ml). The space between the substrate 46 should be as small 
22 (vessel 42 and substrate 46 and other interior as possible to enable released newborn cells to exit the 
components) at speeds that will average the gravity vector bioreactor 22 as Soon as they have been Produced. This 
on the cells. These rotational speeds may be between space is typically approximately 0.1 mm to approximately 
approximately 10 rpm to approximately 50 rpm, and for 0.2 mm. 
example, may be approximately 14 rpm, to average the 30 In alternate embodiments, use of the spacer 50 is optional, 
gravity vector on the cells, as detailed below. and typically spacers are not employed at all. Rather, in these 
The vessel 42 is typically formed such that the outer shell alternate embodiments, a rigid substrate 46 is used, and 
44 and the culture chamber 45 are an integral member. coupled with the rigidity of the Plate 52, the approximately 
However, the outer shell 44 and culture chamber 45 can be 0.1 mm to approximately 0.2 mm gap is uniformly main- 
separate pieces joined together by numerous known tech- 35 tained between the cells 66 and the plate 52, eliminating the 
niques and fasteners. This culture chamber 45 is typically need for the spacer 50. 
recessed and cylindrical in shape, for holding culture The plate 52 includes a vent 74, that allows for bubbles to 
medium or the like. The vessel 42 includes a single access be removed from the chamber 61. It is typically made of 
port 63 or ports, that receive a line 64, through which culture 4o materials, such as Stainless Steel and the like, that are 
medium is supplied to the culture chamber 45 from the sterilizable. The port 70 of the plate 52, typically centrally 
reservoir 28 (as detailed below). The vessel 42 can also be positioned therein, interfaces with the fluid coupler 26. 
disposable if desired. The fluid coupler 26 is stationary, and includes an inlet 
The vessel 42 is typically made of plastic, stainless steel port 80 for receiving culture medium (along a line 76) from 
or other sterilizable material. The culture chamber 45 can 45 the reservoir 28. Within the axle 40 is a passage 84, 
also be lined with plastic or other sterilizable material. When terminating in an exit port 86, to which the line 64 is 
separate pieces, the outer shell 44 and culture chamber 45 attached for transporting culture medium to the vessel 42. A 
are typically made of plastic, stainless steel or any other pump 88, typically a peristaltic pump or the like, typically 
sterilizable material. This culture chamber 45 typically is located along the line 76 between the reservoir 28 and the 
recessed (to a depth “d”) so as to be formed of rigid walls fluid coupler 26, provides the forces for delivering the 
and configured to have a high vertical diameter “V”. This culture medium, in the direction of arrows AA, and forms a 
vertical diameter “V” is larger than the depth “d” to yield system or circuit for delivery of culture medium, from the 
maximum quantities of newborn cells, for example, approxi- reservoir 28 to the vessel 42 (also in the direction of sub 
mately 20 to approximately 30 times larger. arrows BB), and to the substrate 46. This pumping perfuses 
with culture or reaction vessels. This includes valves and grow and divide, as detailed herein. Pumping forces are, for 
membranes that can be penetrated by tubing, syringe, pipette example, approximately 1 m h i n u t e  to approximately 3 
or any other sampling devices. ml/minute for moving culture medium throughout the biore- 
The substrate 46 is typically a porous membrane that actor 22. 
typically accommodates adhesive along its outer surface 68, 60 The bioreactor 22 can be operated at any temperature Or 
to allow cells to attach to this surface 68. This membrane can in any environment, for example, ambient Or gaseous envi- 
be, for example, a 0.22 micron pore-size nitrocellulose filter ronments. The specific temperature and environment is 
manufactured by Millipore, While the substrate 46 is typi- dependent on the desired process or the specific cells being 
cally non-rigid, rigid materials are also suitable, provided used. 
that they will bind with adhesives used to attach the cells (as 65 In an exemplary operation of the system 20, should the 
detailed below). The adhesives used are such that they hold substrate 46 not be fixed in the bioreactor 22, the substrate 
cells to the substrate 46, allowing these cells to grow and 46 is coated with a cell adhesive by passing the cell adhesive 
thereto. 
The access port 63 or ports can be any type of port used 55 the substrate 46 with culture medium, allowing the cells to 
US 6,867,040 B2 
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through it. This is followed by a wash solution of water or 
phosphate buffered saline. Growing cells are then applied to 
the substrate 46. The substrate 46 is clamped to the vessel 42 
while being held vertically. The bioreactor 22 is then turned 
to the normal horizontal operating position, and the pump 28 
is activated to fill the vessel 42 with culture medium. These 
substrate 46 preparation procedures are performed under 
gentle vacuum pressure, such that the flow rate is approxi- 
mately 1 mlisec. 
Alternately, the substrate 46 can be prepared with adhe- 
sive as above, except that the cells have not been added 
while outside of the bioreactor 22. Here, once the prepared 
substrate 46 is in the bioreactor 22, cells are introduced to 
the substrate 46 by pumping cell culture medium into the 
vessel 42 in a direction opposite of arrows AA. Once the 
cells are attached, the pump 28 direction is reversed (to the 
direction of arrows AA) to begin pushing fresh culture 
medium through the bioreactor 22. 
Still alternately, should the substrate 46 be fixed in the 
bioreactor 22 (the bioreactor 22 closed), adhesive, cells, 
wash solutions and cell culture medium are introduced to the 
bioreactor 22 by being pumped therein through the exit port 
30 in the fluid coupler 26. This pumping is in reverse to the 
flow direction described herein (the direction opposite 
arrows AA of FIG. 2). 
In all three situations above, with fresh culture medium 
being pumped through the bioreactor 22, rotation of the 
bioreactor 22 now begins. For example, fresh culture 
medium can be pumped into the culture chamber 45 of the 
vessel 42, to keep it between approximately one quarter to 
approximately full during the course of operation, with an 
approximately half full, or approximately half full to full, 
culture chamber 45 preferred. The vessel 42 and substrate 46 
are rotated, for example, at speeds of approximately 14 rpm. 
At this same time, culture medium is continuously perfused 
into the culture chamber 45 of the vessel 42. The rotation of 
the vessel 42 and substrate 46 coupled with the perfusion of 
culture medium results in the release of newborn (newly 
divided) cells, from the mother cells on the substrate 46. 
These newborn cells are moved in the effluent stream 
through the exit port 70 in the plate 52 and leave the system 
20 through the exit port 30 in the fluid coupler 26, whereby 
they are collected in the flask 32. 
EXAMPLE 
Approximately 5x107 L I210 lymphocytic leukemia were 
attached to a 100 square centimeter nitrocellulose membrane 
filter coated with Concanavalin A (the substrate) under 
vacuum at 1 mlisec. The substrate was now placed into a 
system having a bioreactor as described above, as the 
substrate was clamped into the bioreactor. The culture 
chamber of the vessel was continuously perfused with fresh 
culture medium, at a flow rate of approximately 2 
mliminute. The bioreactor was rotated at speeds of approxi- 
mately 14 rpm. 
Each division of an attached cell resulted in the release of 
one newborn daughter cell from the vessel, while the other 
daughter cell remained attached to the surface of the sub- 
strate. Accordingly, the culture vessel maintained a constant 
cell number, i.e., enabled long-term continuous culture, 
while releasing 5x107 newborn cells each 10 hour genera- 
tion time. 
The process was continued for many generations, and the 
released newborn cells grew synchronously through the cell 
cycle. The cell cycle properties analyzed during rotation 
include mitotic cycle phase durations, cell sizes and DNA 
distributions in the cell cycle. 
6 
The newborn cells increased in size by approximately ten 
percent during the first generation (e.g., 10-12 hours) of 
elution from the culture vessel. During the second genera- 
tion of growth in the vessel, the newborn cells decreased in 
5 size, returning to the initial size at the start of culture in the 
vessel. From this time forward, the size of the newborn cells 
released from the bioreactor remained constant. Once the 
cells adapted to the continuous supply of fresh medium, 
steady state growth ensued and continued for at least eight 
generations of growth. 
The concentration of released cells remained essentially 
constant at 7.5x1O4imin. The released cells were at least 95 
percent pure newborn cells, based on their size distributions 
and G1 content of DNA. The purity of newborn cells 
released from the vessel was maximal when the vessel was 
half filled with medium, here, up to the exit port in the flat 
plate. During subsequent culture, the cells progressed 
through the cycle normally. 
There has been shown and described at least one preferred 
embodiment of cell culture device and system. It is apparent 
2o to those skilled in the art, however, that many changes, 
variations, modifications, and other uses and applications for 
the aforementioned device, system and its components are 
possible, and also such changes, variations, modifications, 
and other uses and applications which do not depart from the 
25 spirit and scope of the invention are deemed to be covered 
by the invention, which is limited only by the claims which 
follow. 
10 
What is claimed is: 
1 .  An apparatus for producing synchronous cells com- 
a) a vessel having a culture chamber with a central axis, 
configured for receiving culture medium, and closed at 
one end by a flat plate having an aperture therein 
located along said central axis of said culture chamber; 
b) a substrate configured for holding cells while allowing 
said cells to divide, said substrate positioned within 
said culture chamber substantially parallel to said flat 
plate and separated from said flat plate by a distance of 
about 0.2 mm or less; 
c) a system for perfusing said substrate with said culture 
medium; and, 
d) a mechanism for rotating said substrate along said 
central axis of said culture chamber; 
wherein culture media received in said vessel traverses a 
path through said substrate and exits the culture cham- 
ber via said aperture in said flat plate. 
30 prising: 
3s 
4o 
45 
2. The apparatus of claim 1,  additionally comprising: 
a spacer positioned between said substrate and said plate. 
3. The apparatus of claim 1,  wherein said substrate is 
4. The apparatus of claim 1,  wherein said substrate is 
5 .  The apparatus of claim 1,  wherein said substrate is 
ss configured for holding adhesive for binding with said cells. 
6. The apparatus of claim 5,  wherein said adhesive is 
selected from at least one of the group consisting of  charged 
molecules, lectins and antibodies. 
7. The apparatus of claim 6, wherein said charged mol- 
8. The apparatus of claim 6, wherein said lectins include 
Concanavalin A. 
9. The apparatus of claim 5, wherein said adhesive 
includes fibronectin. 
10. The apparatus of claim 1, wherein the substrate is 
separated from the flat plate by a distance of about 0.1 mm 
or less. 
SO 
non-rigid. 
rigid. 
60 ecules include poly-D-lysine. 
65 
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11. The apparatus of claim 1, wherein the synchronized 
cells are mammalian cells. 
12. The apparatus of claim 11, wherein the mammalian 
cells are haemopoetic cells. 
13. The apparatus of claim 1, wherein said substrate is 
perfused with said culture medium at a flow rate of at about 
3 ml min-l or less. 
14. The apparatus of claim 13, wherein said flow rate is 
about 1 ml min-l or less. 
15. The apparatus of claim 1, wherein said mechanism for 
rotating rotates the substrate between about 10 rpm and 
about 50 rpm. 
16. The apparatus of claim 15, wherein said mechanism 
for rotating rotates the substrate at about 14 rpm. 
17. A method for producing synchronous cells compris- 
ing: 
a) contacting a substrate with cells, said substrate config- 
ured for holding said cells at least proximate to said 
substrate while allowing said cells to divide thereby 
releasing newborn cells; 
b) positioning said substrate 
i) in a vessel having a culture chamber with a central 
axis, configured for receiving culture medium, and 
closed at one end by a flat plate having an aperture 
therein located along said central axis of said culture 
chamber, and 
ii) substantially parallel to said flat plate and separated 
from said flat plate by a distance of about 0.2 mm or 
less; 
c) rotating said substrate; 
d) introducing a culture medium into said vessel whereby 
said culture medium perfuses through said substrate 
whereby said newborn cells are suspended in said 
culture medium prior to passing out of said culture 
chamber through said aperture; and, 
e) collecting said newborn cells passing out of said 
aperture for a period sufficient to ensure said collected 
newborn cells are synchronized. 
18. The method of claim 17, wherein said holding cells at 
least proximate to said substrate includes attaching cells to 
said substrate. 
19. The method of claim 18, wherein said attaching cells 
to said substrate includes, applying at least one adhesive to 
said substrate. 
20. The method of claim 13, wherein said applying at least 
one adhesive to said substrate includes: providing at least 
one adhesive selected from at least one of the group con- 
sisting of  charged molecules, lectins and antibodies. 
21. The method of claim 20, wherein said charged mol- 
ecules include poly-D-lysine. 
22. The method of claim 20, wherein said lectins include 
Concanavalin A. 
23. The method of claim 19, wherein said applying said 
at least one adhesive to said substrate includes: providing at 
least one adhesive including fibronectin. 
24. The method of claim 17, wherein said perfusing said 
substrate is substantially continuous while said substrate is 
rotating. 
25. The method of claim 17, additionally comprising: 
perfusing said at least one culture medium through said 
bioreactor before rotating said substrate. 
26. The method of claim 17, wherein rotating said sub- 
strate is performed at a rate between about 10 rpm and about 
50 rpm. 
27. The method of claim 26, wherein rotating said sub- 
strate is performed at a rate at about 14 rpm. 
8 
28. The method of claim 17, wherein the synchronized 
cells are mammalian cells. 
29. The apparatus of claim 28, wherein the mammalian 
cells are haemopoetic cells. 
30. The method of claim 17, wherein said period sufficient 
to ensure said newborn cells are synchronized is less than 
about 12 hours. 
31. A method for producing synchronous cells compris- 
ing: 
a) contacting a substrate with cells, whereby said sub- 
strate holds said cells at least proximate to said sub- 
strate while allowing said cells to divide thereby releas- 
ing newborn cells, 
wherein said substrate is: 
i) positioned in a vessel, having a culture chamber with 
a central axis, configured for receiving culture 
medium, and closing at one end by a flat plate having 
an aperture therein located along said central axis of 
said culture chamber, and 
ii) located substantially parallel to said flat plate and 
separated from said flat plate by a distance of about 
0.2 mm or less; 
b) rotating said substrate; 
c) introducing a culture medium into said vessel whereby 
said culture medium perfuses through said substrate 
suspending said newborn cells in said culture medium 
prior to passing out of said culture chamber through 
said aperture; and, 
d) collecting said newborn cells passing out of said 
aperture for a period sufficient to ensure said collected 
newborn cells are synchronized. 
32. The method of claim 31, wherein said contacting said 
substrate with cells includes, applying at least one adhesive 
33. The method of claim 32, wherein said applying at least 
one adhesive to said substrate includes: providing at least 
one adhesive selected from at least one of the group con- 
sisting of  charged molecules, lectins and antibodies. 
34. The method of claim 33, wherein said charged mol- 
ecules include poly-D-lysine. 
35. The method of claim 33, wherein said lectins include 
Concanavalin A. 
36. The method of claim 32, wherein said applying said 
45 at least one adhesive to said substrate includes: providing at 
least one adhesive including fibronectin. 
37. The method of claim 31, wherein rotating said sub- 
strate is performed at a rate between about 10 rpm and about 
50 rpm. 
38. The method of claim 37, wherein rotating said sub- 
strate is performed at a rate at about 14 rpm. 
39. The method of claim 31, wherein said period sufficient 
to ensure said newborn cells are synchronized is less than 
about 12 hours. 
40. The method of claim 31, wherein the synchronized 
cells are mammalian cells. 
41. The method of claim 40, wherein the mammalian cells 
are haemopoetic cells. 
42. An apparatus for producing synchronous cells com- 
a) a vessel having a culture chamber with a central axis, 
configured for receiving culture medium, and closed at 
one end by a flat plate having an aperture therein 
located along said central axis of said culture chamber; 
b) a substrate configured for holding cells while allowing 
said cells to divide and release newborn cells, said 
substrate positioned within said culture chamber sub- 
s 
10 
15 
20 
25 
3o 
35 to said substrate. 
4o 
55 
6o prising: 
65 
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stantially parallel to said flat plate and separated from 
said flat plate by a distance of about 0.2 mm of less; 
c) a system for perfusing said substrate with said culture 
medium; 
d) a mechanism for rotating said substrate along said 
central axis of said culture chamber; and, 
e) a system for collecting the newborn cells fluidly linked 
to said culture chamber, 
wherein culture media received in said vessel traverses a 
path through said substrate and exits the culture cham- 
ber via said aperture in said flat plate. 
43. The apparatus of claim 42, additionally comprising: 
a spacer, positioned between said substrate and said plate. 
44. The apparatus of claim 42, wherein said substrate is IS 
non-rigid. 
45. The apparatus of claim 42, wherein said substrate is 
rigid. 
46. The apparatus of claim 42, wherein said substrate is 
configured for holding adhesive for binding with said cells. 20 
47. The apparatus of claim 46, wherein said adhesive is 
selected from at least one of the group consisting of  charged 
molecules, lectins and antibodies. 
48. The apparatus of claim 47, wherein said charged 
molecules include poly-D-lysine. 
10 
49. The apparatus of claim 47, wherein said lectins 
include Concanavalin A. 
50. The apparatus of claim 46, wherein said adhesive 
includes fibronectin. 
51. The method of claim 42, wherein the substrate is 
separated from the flat plate by a distance of about 0.1 mm 
or less. 
52. The method of claim 42, wherein said substrate is 
perfused with said culture medium at a flow rate of at about 
3 ml min-l or less. 
53. The apparatus of claim 52, wherein said flow rate is 
about 1 ml min-l or less. 
54. The apparatus of claim 42, wherein said mechanism 
for rotating rotates the substrate between about 10 rpm and 
about 50 rpm. 
55. The apparatus of claim 54, wherein said mechanism 
for rotating rotates the substrate at about 14 rpm. 
56. The apparatus of claim 42, wherein the synchronized 
cells are mammalian cells. 
57. The apparatus of claim 56, wherein the mammalian 
cells are haemopoetic cells. 
* * * * *  
